A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Esomeprazole 20 mg Once Daily in Subjects With Frequent Heartburn.
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2016
At a glance
- Drugs Esomeprazole (Primary)
- Indications Heartburn
- Focus Registrational; Therapeutic Use
- Acronyms NEXT2
- Sponsors AstraZeneca
- 16 Jan 2012 Actual patient no 526 added as reported by ClinicalTrials.gov.
- 16 Jan 2012 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 16 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.